{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:11:56Z","timestamp":1778926316658,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23DK129762-03"],"award-info":[{"award-number":["K23DK129762-03"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003086","name":"Eusko Jaurlaritza","doi-asserted-by":"publisher","award":["2020111061"],"award-info":[{"award-number":["2020111061"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10620-025-09400-5","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T02:34:09Z","timestamp":1758249249000},"page":"578-583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence and Clinical Features of Incidental Inflammatory Bowel Disease Identified During Screening and Surveillance Colonoscopy"],"prefix":"10.1007","volume":"71","author":[{"given":"Sergio","family":"Bronze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabari","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manasi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros D.","family":"Polydorides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iago","family":"Rodr\u00edguez-Lago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan C.","family":"Ungaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"9400_CR1","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","volume":"383","author":"JT Chang","year":"2020","unstructured":"Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med 2020;383:2652\u20132664. https:\/\/doi.org\/10.1056\/NEJMra2002697.","journal-title":"N Engl J Med"},{"key":"9400_CR2","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn\u2019s disease. Lancet 2017;389:1741\u20131755. https:\/\/doi.org\/10.1016\/S0140-6736(16)31711-1.","journal-title":"Lancet"},{"key":"9400_CR3","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet 2017;389:1756\u20131770. https:\/\/doi.org\/10.1016\/S0140-6736(16)32126-2.","journal-title":"Lancet"},{"key":"9400_CR4","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","volume":"140","author":"J Cosnes","year":"2011","unstructured":"Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140:1785-1794.e4. https:\/\/doi.org\/10.1053\/j.gastro.2011.01.055.","journal-title":"Gastroenterology"},{"key":"9400_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/gut.30.4.481","volume":"30","author":"JF Mayberry","year":"1989","unstructured":"Mayberry JF, Ballantyne KC, Hardcastle JD, Mangham C, Pye G. Epidemiological study of asymptomatic inflammatory bowel disease: the identification of cases during a screening programme for colorectal cancer. Gut 1989;30:481\u2013483. https:\/\/doi.org\/10.1136\/gut.30.4.481.","journal-title":"Gut"},{"key":"9400_CR6","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.cgh.2017.11.006","volume":"16","author":"I Rodr\u00edguez-Lago","year":"2018","unstructured":"Rodr\u00edguez-Lago I, Merino O, Azagra I et al. Characteristics and progression of preclinical inflammatory bowel disease. Clin Gastroenterol Hepatol 2018;16:1459\u20131466. https:\/\/doi.org\/10.1016\/j.cgh.2017.11.006.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9400_CR7","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.cgh.2020.06.069","volume":"19","author":"H Yanai","year":"2021","unstructured":"Yanai H, Shachar E, Ben-Horin S et al. Early indolent course of Crohn\u2019s disease in newly diagnosed patients is not rare and possibly predictable. Clin Gastroenterol Hepatol 2021;19:1564-1572.e5. https:\/\/doi.org\/10.1016\/j.cgh.2020.06.069.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9400_CR8","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.crohns.2014.03.002","volume":"8","author":"SK Park","year":"2014","unstructured":"Park SK, Ye BD, Yang SK et al. Clinical features and course of ulcerative colitis diagnosed in asymptomatic subjects. J Crohns Colitis 2014;8:1254\u20131260. https:\/\/doi.org\/10.1016\/j.crohns.2014.03.002.","journal-title":"J Crohns Colitis"},{"key":"9400_CR9","doi-asserted-by":"publisher","first-page":"S170","DOI":"10.1002\/ibd.20596","volume":"14","author":"RD Johnston","year":"2008","unstructured":"Johnston RD, Logan RFA. How often is IBD diagnosed incidentally at screening colonoscopy done for colorectal cancer surveillance or other reasons? Inflamm Bowel Dis 2008;14:S170\u2013S171. https:\/\/doi.org\/10.1002\/ibd.20596.","journal-title":"Inflamm Bowel Dis"},{"key":"9400_CR10","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1093\/ecco-jcc\/jjab030","volume":"15","author":"M Agrawal","year":"2021","unstructured":"Agrawal M, Miranda MB, Walsh S, Narula N, Colombel JF, Ungaro RC. Prevalence and progression of incidental terminal ileitis on non-diagnostic colonoscopy: a systematic review and meta-analysis. J Crohns Colitis 2021;15:1455\u20131463. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab030.","journal-title":"J Crohns Colitis"},{"key":"9400_CR11","doi-asserted-by":"publisher","first-page":"otac034","DOI":"10.1093\/crocol\/otac034","volume":"360","author":"A Grinman","year":"2022","unstructured":"Grinman A, Ungar B, Lahat A, Kopylov U, Eliakim R, Ben-Horin S. Incidentally diagnosed asymptomatic Crohn\u2019s disease: a retrospective cohort study of long-term clinical outcomes. Crohns Colitis 2022;360:otac034. https:\/\/doi.org\/10.1093\/crocol\/otac034.","journal-title":"Crohns Colitis"},{"key":"9400_CR12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.dld.2020.07.036","volume":"53","author":"C Bezzio","year":"2021","unstructured":"Bezzio C, Manes G, Schettino M et al. Inflammatory bowel disease in a colorectal cancer screening population: diagnosis and follow-up. Dig Liver Dis 2021;53:587\u2013591. https:\/\/doi.org\/10.1016\/j.dld.2020.07.036.","journal-title":"Dig Liver Dis"},{"key":"9400_CR13","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/apt.17370","volume":"57","author":"N Jayasooriya","year":"2023","unstructured":"Jayasooriya N, Baillie S, Blackwell J et al. Systematic review with meta-analysis: time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease. Aliment Pharmacol Ther 2023;57:635\u2013652. https:\/\/doi.org\/10.1111\/apt.17370.","journal-title":"Aliment Pharmacol Ther"},{"key":"9400_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","volume":"5","author":"GBD","year":"2017","unstructured":"GBD. Inflammatory Bowel Disease Collaborators (2019) The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2017;5:17\u201330. https:\/\/doi.org\/10.1016\/S2468-1253(19)30333-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"9400_CR15","doi-asserted-by":"publisher","first-page":"i79","DOI":"10.1093\/ecco-jcc\/jjad212.0045","volume":"18","author":"J Rev\u00e9s","year":"2024","unstructured":"Rev\u00e9s J, Roager Madsen G, Burisch J et al. DOP05 bowel damage and its correlation with the disability index in patients with recently diagnosed Crohn\u2019s disease. J Crohns Colitis 2024;18:i79\u2013i80. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad212.0045.","journal-title":"J Crohns Colitis"},{"key":"9400_CR16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00384-024-04660-5","volume":"39","author":"I Rodr\u00edguez-Lago","year":"2024","unstructured":"Rodr\u00edguez-Lago I, Aduna M, Ram\u00edrez de la Piscina P et al. Transmural cross-sectional findings and bowel damage assessment in preclinical Crohn\u2019s disease: a case-control study. Int J Colorectal Dis 2024;39:92. https:\/\/doi.org\/10.1007\/s00384-024-04660-5.","journal-title":"Int J Colorectal Dis"},{"key":"9400_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4253\/wjge.v4.i6.201","volume":"4","author":"R Rameshshanker","year":"2012","unstructured":"Rameshshanker R, Arebi N. Endoscopy in inflammatory bowel disease: when and why. World J Gastrointest Endosc 2012;4:201\u2013211. https:\/\/doi.org\/10.4253\/wjge.v4.i6.201.","journal-title":"World J Gastrointest Endosc"},{"key":"9400_CR18","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.dld.2020.05.052","volume":"52","author":"I Rodr\u00edguez-Lago","year":"2020","unstructured":"Rodr\u00edguez-Lago I, Ram\u00edrez C, Merino O et al. Early microscopic findings in preclinical inflammatory bowel disease. Dig Liver Dis 2020;52:1467\u20131472. https:\/\/doi.org\/10.1016\/j.dld.2020.05.052.","journal-title":"Dig Liver Dis"},{"key":"9400_CR19","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749\u2013753. https:\/\/doi.org\/10.1136\/gut.2005.082909.","journal-title":"Gut"},{"key":"9400_CR20","doi-asserted-by":"publisher","first-page":"22967","DOI":"10.1038\/s41598-024-73817-7","volume":"14","author":"H Bedi","year":"2024","unstructured":"Bedi H, Telford J, Penner R et al. Inflammatory bowel disease uncovered in fecal immunochemical test positive patients in a Canadian provincial colon cancer screening program. Sci Rep 2024;14:22967. https:\/\/doi.org\/10.1038\/s41598-024-73817-7.","journal-title":"Sci Rep"},{"key":"9400_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251338647","author":"I Rodr\u00edguez-Lago","year":"2025","unstructured":"Rodr\u00edguez-Lago I, Marigorta UM, Mateos B, Ma\u00f1osa M, M\u00e1rquez-Mosquera L, Mench\u00e9n L, Rodr\u00edguez-Moranta F, Alonso I, Aguas M, Alonso-Gal\u00e1n H, Borr\u00e0s P, Castro B, Dom\u00e8nech E et al. Natural history, immunological and genetic characteristics of preclinical inflammatory bowel disease (EARLY): study protocol for a prospective cohort study. Ther Adv Gastroenterol. 2025. https:\/\/doi.org\/10.1177\/17562848251338647.","journal-title":"Ther Adv Gastroenterol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09400-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09400-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09400-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T08:01:46Z","timestamp":1772092906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09400-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["9400"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09400-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SB has no conflicts to disclose. SS has no conflicts to disclose. MA is reports consulting fees from Douglas Pharmaceutical. JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals, Prometheus, Takeda, and Bristol Myers Squibb; receiving payment for lectures from AbbVie, and Takeda; receiving consulting fees from AbbVie, Amgen, AnaptysBio, Allergan, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Celltrion, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Glaxo Smith Kline, Genentech (Roche), Janssen Pharmaceuticals, Kaleido Biosciences, Immunic, Invea, Iterative Scopes, Merck, Landos, Microba Life Science, Novartis, Otsuka Pharmaceutical, Pfizer, Protagonist Therapeutics, Prometheus, Sanofi, Seres, Takeda, Teva, TiGenix, Vifor; and hold stock options in Intestinal Biotech Development. IRL has received financial support for traveling and educational activities from or has served as an advisory board member for Abbvie, Adacyte, Biogen, Celltrion, Chiesi, Faes Farma, Ferring, Fresenius Kabi, Galapagos, Janssen, Lilly, Mirum Pharmaceuticals, MSD, Pfizer, Roche, Takeda, and Tillotts Pharma; and research support from AbbVie. RU has served as a consultant and\/or advisory board member for AbbVie, Bristol Myers Squibb, Celltrion, Genentech, Inotrem, Lilly, Janssen, Pfizer, Roivant, and Takeda and has received research funding from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}